A A A
-->

Nierenzellkarzinom

Klinische Studien

A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
Ansprechpartner:
Prof. Dr. med. A. Hegele
Dr. med. L. Skrobek

Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma
- SWITCH 2 Study –
Ansprechpartner:
Prof. Dr. med. A. Hegele
Dr. C. Keil
Hr. F. Brüning

A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma
Ansprechpartner:
Prof. Dr. med. A. Hegele
Hr. F. Brüning
Hr. C. Klapp